Tagged with Researc

Egypt Ashraf Elkhouly, executive director of the Egyptian Society for Pharmaceutical Research, discusses how recent healthcare reforms will help to attract more investment to Egypt and the importance of public-private partnerships for improving the country’s healthcare system.   In collaboration with the government, we started to look into possibilities on how…

China TJ Deng, GM China and BioDuro Discovery; and Ian Wisenberg, CFO of BioDuro, share the strategic rationale behind Advent International’s 2019 investment into the company; the focus of BioDuro 4.0 on growth, particularly in the US and Chinese markets; the differentiated and value-added services BioDuro can offer clients; and their…

China Amidst the sea of Big Pharma executives jumping ship to start highly regarded and attention-grabbing biotech companies, bolstered by the huge influx of capital, the opening of stock exchanges in first Hong Kong and subsequently Shanghai to pre-profit biotech companies that meet certain criteria, as well as the reformation and…

France Faten Hidri, VP for Higher Education & Research in the Paris Region (Ile de France), discusses the vital role of academic research and the life sciences in her region and ongoing collaboration with other European stakeholders.   While the Paris region is the European leader in terms of patent filings,…

France Bertrand Sohier, VP and general manager business and administration of Parexel France discusses the latest trends impacting the clinical research environment of the country, gives insight on the strategies the company utilizes to differentiate itself from competitors, and shares the importance of keeping a patient-focused mentality at the core of…

France Jean-Marc Grognet, general manager of Genopole, France’s leading biotechnology cluster, explains the organization’s unique triangular structure with the corner points of the cluster being higher education, research, and industry. Grognet goes on to elaborate on the cluster’s extensive scientific offering and his ambitions to build a collaborative network of life…

Opinion Rhenu Buller, an expert on disruptive technologies at business consultancy Frost & Sullivan’s Asia Pacific office, outlines the technological innovations currently driving the drug development pipelines of rare disease companies.   Recent advancements in the development of novel platforms for precise targeting of small molecules, gene therapy, stem cell therapy,…

Korea Dr Jin Hyoung Kang, president of the Cancer Study Group comments on the scope for oncology drug development in Korea, and the issues resulting from the structure of Korea’s healthcare system. Dr Kang also offers his foresight in relation to the greater role AI and big data will play within…

Korea Established in 1986, the KDRA is Korea’s leading new drug research and development special corporation, established under the Ministry of Science and ICT and composed of 350 members. Its executive director, Jae Cheon Yeo, explains the crucial role the organization plays in promoting R&D in Korea, the evolution of the…

China Jay Dong, founding GM (China and APAC) and Global VP of Cell Signaling Technology, shares the company’s success in the past ten years; the economic transformation in China driving the growth of the biotech and pharma industries; the cutting-edge solutions and technologies Cell Signaling Technology is committed to providing to…

Spain Silvia Casellas, CEO of Anagram, a Spanish CRO, discusses the challenges of the consolidation process the company has gone in recent years, the reasons for the boom in Spain’s clinical trials ecosystem, and the importance of a close-knit client-to-service-provider relationship for CROs today.   We are the first Spanish company…

China Dr Lingshi Tan, chairman and CEO of dMed, shares his strategic insights into the new era of Chinese biotech innovation and how it motivated him to leave Pfizer to establish dMed; the mission of dMed as ‘more than a CRO’ to support the growth of the Chinese biotech industry; their…